REPLY
AIDS Clinical Trials Group Study Numbers
Margaret A. Fischl, MD;
Kenneth Stanley, PhD; and
Ann C. Collier, MD
1 September 1995 | Volume 123 Issue 5 | Page 395
IN RESPONSE:
Dr. von Reyn proposes an interesting precedent. We had not initially included the ACTG protocol number for this study to avoid ACTG jargon or vernacular. However, Dr. von Reyn is correct in that presentations and discussions of ACTG studies frequently refer to these studies by their ACTG protocol number. Dr. von Reyn has also correctly cited our study [1] as ACTG 155.
|
Author and Article Information
|
|---|
University of Miami School of Medicine; Miami, FL 33101
Harvard School of Public Health; Boston, MA 02115
University of Washington; Seattle, WA 98104
1. Fischi MA. Stanley K, Collier AC, Ardunio JM, Stein DS, Feinberg JE, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advance HIV disease. Ann Intern Med. 1995; 122:24-32.
About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Top
Author & Article Info
References
Article
